The pathogenesis of human presenile and senile demetias will be investigated in rodent models developed in this laboratory. In these models human Creutzfeldt-Jakob disease (CJD) and related dementias associated with aging are transmitted to small laboratory animals. In he experimental disease, as in many human dementias, there is a chronic and nonremitting course, and pathological lesions are entirely restricted to the CNS, without any inflammatory reactions. Our long term goal is to use these models to unravel common pathways in the production of human dementias and aging. Events that are obscured or inaccessible in end stages of the human disease can be clarified by study of early stages in experimental models. We intend to isolate more primary agents from human senile and presenile dementias, and to define overlapping and/or characteristics of lesions in these. Lesions in models will be compared with lesions occurring in aging, using temporal studies and a variety of morphological techniques. Isolation of variant strains of the CJ agent will be attempted in inbred strains of hamsters, evaluating variations in clinical signs and lesion profiles. The efficacy of HPA-23, found to be effective in scrapie will be tested in experimental CJD, and evaluated for lesion production and mode of action. Age related maturation of resistance of lymphoreticular cells will be tested and infectivity of subpopulations of these cells investigated. Brain subfractions will be systematically evaluated with special emphasis on RNA species and in vitro analysis. The studies have wide ramifications for reevaluation and approach as to the group of human dementias.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG003106-04
Application #
3090657
Study Section
Aging Review Committee (AGE)
Project Start
1982-09-30
Project End
1987-08-31
Budget Start
1985-09-01
Budget End
1986-08-31
Support Year
4
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Yale University
Department
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
DeGiorgio, Lorraine A; Manuelidis, Laura; Bernstein, Jerald J (2002) Transient appearance of amyloid precursor protein plaques in the brain of thymectomized rats after human leptomeningeal cell grafts. Neurosci Lett 322:62-6
Behar, K L; Boucher, R; Fritch, W et al. (1998) Changes in N-acetylaspartate and myo-inositol detected in the cerebral cortex of hamsters with Creutzfeldt-Jakob disease. Magn Reson Imaging 16:963-8
Manuelidis, L (1994) The dimensions of Creutzfeldt-Jakob disease. Transfusion 34:915-28
Sklaviadis, T; Dreyer, R; Manuelidis, L (1992) Analysis of Creutzfeldt-Jakob disease infectious fractions by gel permeation chromatography and sedimentation field flow fractionation. Virus Res 26:241-54
Taruscio, D; Manuelidis, L (1991) Integration site preferences of endogenous retroviruses. Chromosoma 101:141-56
Manuelidis, E E; Manuelidis, L (1991) Search for a transmissible agent in Alzheimer's disease: studies of human buffy coat. Curr Top Microbiol Immunol 172:275-80
Akowitz, A; Sklaviadis, T; Manuelidis, E E et al. (1990) Nuclease-resistant polyadenylated RNAs of significant size are detected by PCR in highly purified Creutzfeldt-Jakob disease preparations. Microb Pathog 9:33-45
Murdoch, G H; Sklaviadis, T; Manuelidis, E E et al. (1990) Potential retroviral RNAs in Creutzfeldt-Jakob disease. J Virol 64:1477-86
Sklaviadis, T; Akowitz, A; Manuelidis, E E et al. (1990) Nuclease treatment results in high specific purification of Creutzfeldt-Jakob disease infectivity with a density characteristic of nucleic acid-protein complexes. Arch Virol 112:215-28
Sklaviadis, T K; Manuelidis, L; Manuelidis, E E (1989) Physical properties of the Creutzfeldt-Jakob disease agent. J Virol 63:1212-22

Showing the most recent 10 out of 31 publications